<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32773451</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-6551</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Current opinion in neurology</Title><ISOAbbreviation>Curr Opin Neurol</ISOAbbreviation></Journal><ArticleTitle>Molecular pathogenesis of spinal bulbar muscular atrophy (Kennedy's disease) and avenues for treatment.</ArticleTitle><Pagination><StartPage>629</StartPage><EndPage>634</EndPage><MedlinePgn>629-634</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/WCO.0000000000000856</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW">The aim of this study was to illustrate the current understanding and avenues for developing treatment in spinal and bulbar muscular atrophy (SBMA), an inherited neuromuscular disorder caused by a CAG trinucleotide repeat expansion in the androgen receptor (AR) gene.</AbstractText><AbstractText Label="RECENT FINDINGS">Important advances have been made in characterizing the molecular mechanism of the disease, including the disruption of protein homeostasis, intracellular trafficking and signalling pathways. Biomarkers such as MRI quantification of muscle volume and fat fraction have been used to track disease progression, and will be useful in future clinical studies. Therapies tested and under development have been based on diverse strategies, including targeting mutant AR gene expression, stability and activity, and pathways that mitigate disease toxicity.</AbstractText><AbstractText Label="SUMMARY">We provide an overview of the recent advances in understanding the SBMA disease mechanism and highlight efforts to translate these insights into well tolerated and effective therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grunseich</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischbeck</LastName><ForeName>Kenneth H</ForeName><Initials>KH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z99 NS999999</GrantID><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Opin Neurol</MedlineTA><NlmUniqueID>9319162</NlmUniqueID><ISSNLinking>1350-7540</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="N">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011944" MajorTopicYN="N">Receptors, Androgen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019680" MajorTopicYN="Y">Trinucleotide Repeat Expansion</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflicts of interest. There are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32773451</ArticleId><ArticleId IdType="mid">NIHMS1651360</ArticleId><ArticleId IdType="pmc">PMC7748295</ArticleId><ArticleId IdType="doi">10.1097/WCO.0000000000000856</ArticleId><ArticleId IdType="pii">00019052-202010000-00013</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset: a sex-linked recessive trait. Neurology 1968; 18:671&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">4233749</ArticleId></ArticleIdList></Reference><Reference><Citation>LaSpada AR, Wilson EM, Lubahn DB, et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991; 352:77&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">2062380</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes LE, Freeman BK, Auh S, et al. Clinical features of spinal and bulbar muscular atrophy. Brain 2009; 132:3242&#x2013;3251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2792370</ArticleId><ArticleId IdType="pubmed">19846582</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Rhodes LE, Kokkinis AD, White MJ et al. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomized placebo-controlled trial. Lancet Neurol 2011; 10:140&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056353</ArticleId><ArticleId IdType="pubmed">21216197</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Adachi H, Kume A, et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 2002; 35:843&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pubmed">12372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath S, Munsie LN, Truant R. A huntingtin-mediated fast stress response halting endosomal trafficking is defective in Huntington&#x2019;s disease. Hum Mol Genet 2015; 24:450&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4275073</ArticleId><ArticleId IdType="pubmed">25205111</ArticleId></ArticleIdList></Reference><Reference><Citation>Santana MM, Paixao S, Cunha-Santos J et al. Trehalose alleviates the phenotype of Machado-Joseph disease mouse models. J Transl Med 2020; 18:161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7144062</ArticleId><ArticleId IdType="pubmed">32272938</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes CJ, Miranda HC, Frankowski H, et al. Polyglutamine-expanded androgen receptor interferes with TFEB to elicit autophagy defects in SBMA. Nat Neurosci 2014; 17:1180&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4180729</ArticleId><ArticleId IdType="pubmed">25108912</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua JP, Reddy SL, Merry DE, et al. Transcriptional activation of TFEB/ZKSCAN3 target genes underlies enhanced autophagy in spinobulbar muscular atrophy. Hum Mol Genet 2014; 23:1376&#x2013;1386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3919011</ArticleId><ArticleId IdType="pubmed">24150846</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicardi ME, Cristofani R, Crippa V, et al. Autophagic and proteasomal mediated removal of mutant androgen receptor in muscle models of spinal and bulbar muscular atrophy. Front Endocrinol 2019; 10:569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6710630</ArticleId><ArticleId IdType="pubmed">31481932</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusmini P, Cortese K, Crippa V, et al. Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration. Autophagy 2019; 15:631&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6526812</ArticleId><ArticleId IdType="pubmed">30335591</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold FJ, Pluciennik A, Merry DE. Impaired nuclear export of polyglutamine-expanded androgen receptor in spinal and bulbar muscular atrophy. Sci Rep 2019; 9:119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6333819</ArticleId><ArticleId IdType="pubmed">30644418</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Lu Y, Lopez-Gonzalez R et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature 2015; 525:129&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Grima JC, Daigle JG, Arbez N et al. Mutant Huntingtin Disrupts the nuclear pore complex. Neuron 2017; 94:93&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5595097</ArticleId><ArticleId IdType="pubmed">28384479</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyubchenko YL, Krasnoslobodtsev, Luca S. Fibrillogenesis of huntingtin and other glutamine containing proteins. Subcell Biochem 2012; 65:225&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4226413</ArticleId><ArticleId IdType="pubmed">23225006</ArticleId></ArticleIdList></Reference><Reference><Citation>Escobedo A, Topal B, Kunze MBA et al. Side chain to main chain hydrogen bonds stabilize a polyglutamine helix in a transcription factor. Nat Commun 2019; 10:2034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6497633</ArticleId><ArticleId IdType="pubmed">31048691</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright PE, Dyson HJ. Intrinsically disordered proteins in cellular signaling and regulation. Nat Rev Mol Cell Biol 2015; 16:18&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4405151</ArticleId><ArticleId IdType="pubmed">25531225</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol ED, Szulc E, Sanza CD et al. Regulation of androgen receptor activity by transient interactions of its transactivation domain with general transcription regulators. Structure 2018; 26:145&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5830076</ArticleId><ArticleId IdType="pubmed">29225078</ArticleId></ArticleIdList></Reference><Reference><Citation>Badders NM, Korff A, Miranda HC et al. Selective modulation of the androgen receptor AF2 domain rescues degeneration in spinal bulbar muscular atrophy. Nature Medicine 2018; 24:427&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5975249</ArticleId><ArticleId IdType="pubmed">29505030</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik B, Devine H, Patani R et al. Gene expression analysis reveals early dysregulation of disease pathways and links Chmp7 to pathogenesis of spinal and bulbar muscular atrophy. Sci Rep 2019; 9:3539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6401132</ArticleId><ArticleId IdType="pubmed">30837566</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo N, Tohnai G, Sahashi K et al. DNA methylation inhibitor attenuates polyglutamine-induced neurodegeneration by regulating Hes5. EMBO Mol Med 2019; 11: e8547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6505579</ArticleId><ArticleId IdType="pubmed">30940675</ArticleId></ArticleIdList></Reference><Reference><Citation>Iida M, Sahashi K, Kondo N et al. Src inhibition attenuates polyglutamine-mediated neuromuscular degeneration in spinal and bulbar muscular atrophy. Nature Communications 2019; 10:4262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6753158</ArticleId><ArticleId IdType="pubmed">31537808</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath SR, Lieberman ML, Yu Z et al. MEF2 impairment underlies skeletal muscle atrophy in polyglutamine disease. Acta Neuropathologica 2020; [Epub ahead of print].</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166004</ArticleId><ArticleId IdType="pubmed">32306066</ArticleId></ArticleIdList></Reference><Reference><Citation>Halievski K, Nath SR, Katsuno M et al. Disease affects bdnf expression in synaptic and extrasynaptic regions of skeletal muscle of three SBMA mouse models. Int J Mol Sci 2019; 20:1314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6470984</ArticleId><ArticleId IdType="pubmed">30875922</ArticleId></ArticleIdList></Reference><Reference><Citation>Chivet M, Marchioretti C, Pirazzini M et al. Polyglutamine-expanded androgen receptor alteration of skeletal muscle homeostasis and myonuclear aggregation are affected by sex, age, and muscle metabolism. Cells 2020; 9:325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7072234</ArticleId><ArticleId IdType="pubmed">32019272</ArticleId></ArticleIdList></Reference><Reference><Citation>Greensmith L, Pradat PF, Soraru G et al. 241st ENMC international workshop: Towards a European unifying lab for Kennedy&#x2019;s disease. 15&#x2013;17th February, 2019 Hoofddorp, The Netherlands. Neuromuscular Disorders 2019; 29:716&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pubmed">31488386</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahlqvist JR, Fornander F, De Stricker Borch J et al. Disease progression and outcome measures in spinobulbar muscular atrophy. Ann Neurol 2018; 84:762&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">30255951</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijikata Y, Hashizume A, Yamada S et al. Biomarker-based analysis of preclinical progression in spinal and bulbar muscular atrophy. Neurology 2018; 90:e1501&#x2013;e1509.</Citation><ArticleIdList><ArticleId IdType="pubmed">29572281</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahlqvist JR, Oestergaard ST, Poulsen NS et al. Refining the spinobulbar muscular atrophy phenotype by quantitative MRI and clinical assessments. Neurology 2019; 92:e548&#x2013;e559.</Citation><ArticleIdList><ArticleId IdType="pubmed">30610091</ArticleId></ArticleIdList></Reference><Reference><Citation>Klickovic U, Zampedri L, Sinclair CDJ et al. Skeletal muscle MRI differentiates SBMA and ALS and correlates with disease severity. Neurology 2019; 93:e895&#x2013;e907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6745729</ArticleId><ArticleId IdType="pubmed">31391248</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyata M, Kakeda S, Hashimoto T et al. The facial nerve atrophy with spinal and bulbar muscular atrophy pateints (SBMA): Three case reports with 3D fast imaging employing steady-state acquisition (FIESA). Journal of the Neurological Sciences 2019; 406:116461.</Citation><ArticleIdList><ArticleId IdType="pubmed">31634716</ArticleId></ArticleIdList></Reference><Reference><Citation>Francini-Pesenti F, Querin G, Martini C et al. Prevalence of metabolic syndrome and non-alcoholic fatty liver disease in a cohort of Italian patients with spinal-bulbar muscular atrophy. Acta Myologica 2018; 37:204&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6390113</ArticleId><ArticleId IdType="pubmed">30838350</ArticleId></ArticleIdList></Reference><Reference><Citation>Guber RD, Takyar V, Kokkinis A et al. Nonalcoholic fatty liver disease in spinal and bulbar muscular atrophy. Neurology 2017; 89:2481&#x2013;2490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5729799</ArticleId><ArticleId IdType="pubmed">29142082</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan A, Rao MV, Veeranna, Nixon RA. Neurofilaments and neurofilament proteins in health and disease. Cold Spring Harb Perspect Biol 2017; 9:a018309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5378049</ArticleId><ArticleId IdType="pubmed">28373358</ArticleId></ArticleIdList></Reference><Reference><Citation>Darras BT, Crawford TO, Finkel RS et al. Neurofilament as a potential biomarker for spinal muscular atrophy. Ann Clin Transl Neurol 2019; 6:932&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6530526</ArticleId><ArticleId IdType="pubmed">31139691</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Feneberg E, Weishaupt J et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 2016; 87:12&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardi V, Querin G, Ziff OJ et al. Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy. Neurology 2019; 92:e1205&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6511101</ArticleId><ArticleId IdType="pubmed">30787165</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardi V, Bombaci A, Zampedri L et al. Plasma pNfH levels differentiate SBMA from ALS. J Neurol Neurosurg Psychiatry 2020; 91:215&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">31575607</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Ren Y, Zhu W et al. Phosphorylated neurofilament heavy chain levels in paired plasma and CSF of amyotrophic lateral sclerosis. J Neurol Sci 2016; 367:269&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">27423602</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahlqvist JR, Oestergaard ST, Poulsen NS et al. Muscle contractility in spinobulbar muscular atrophy. Sci Rep 2019; 9:4680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6423126</ArticleId><ArticleId IdType="pubmed">30886222</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka S, Hashizume A, Hijikata Y et al. Nasometric scores in spinal and bulbar muscular atrophy- Effects on palatal lift prosthesis on dysarthria and dysphagia. J Neurol Sci 2019; 407:116503.</Citation><ArticleIdList><ArticleId IdType="pubmed">31669728</ArticleId></ArticleIdList></Reference><Reference><Citation>Giorgia Q, Irene B, Laura M et al. Preliminary design and validation of the &#x201c;6-K-scale&#x201d; for bulbar symptoms evaluation in SBMA. Neurol Sci 2019; 40:1393&#x2013;1401.</Citation><ArticleIdList><ArticleId IdType="pubmed">30915613</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcato S, Kleinbub JR, Querin G. et al. Unimpaired neuropsychological performace and enhanced memory recall in patients with SBMA: A large sample comparative study. Sci Rep 2018; 8:13627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6134140</ArticleId><ArticleId IdType="pubmed">30206283</ArticleId></ArticleIdList></Reference><Reference><Citation>Banno H, Katsuno M, Suzuki K et al. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol 2009; 65:140&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">19259967</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Banno H, Suzuki K et al. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomized, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9:875&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">20691641</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Katsuno M, Suzuki K et al. Efficacy and safety of leuprorelin acetate for subjects with spinal and bulbar muscular atrophy: pooled analyses of two randomized-controlled trials. J Neurol 2019; 266:1211&#x2013;1221.</Citation><ArticleIdList><ArticleId IdType="pubmed">30847645</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Kastuno M,Suzuki K et al. Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy: natural history-controlled study. J Neurol Neurosurg Psychiatry 2017; 88:1026&#x2013;1032.</Citation><ArticleIdList><ArticleId IdType="pubmed">28780536</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva AC, Lobo DD, Martins IM et al. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders. Brain 2020; 143:407&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">31738395</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabrizi SJ, Leavitt BR, Landwehrmeyer GB et al. Targeting huntingtin expression in patients with huntington&#x2019;s disease. N Engl J Med 2019; 380:2307&#x2013;2316.</Citation><ArticleIdList><ArticleId IdType="pubmed">31059641</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Hu C, El Achkar M et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N Engl J Med 2019; 381:1644&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6961983</ArticleId><ArticleId IdType="pubmed">31597037</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman A, Yu Z, Murray S et al. Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. Cell Rep 2014; 7:774&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4356525</ArticleId><ArticleId IdType="pubmed">24746732</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahashi K, Katsuno M, Hung G et al. Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 2015; 24:5985&#x2013;5994.</Citation><ArticleIdList><ArticleId IdType="pubmed">26231218</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z, Chang Y, Yu I-C et al. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nature Medicine 2007; 13:348&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">17334372</ArticleId></ArticleIdList></Reference><Reference><Citation>Bott LC, Badders NM, Chen K et al. A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy. Hum Mol Genet 2016; 25:1979&#x2013;1989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5062587</ArticleId><ArticleId IdType="pubmed">26962150</ArticleId></ArticleIdList></Reference><Reference><Citation>Christiansen AR, Lipshultz LI, Hotaling JM et al. Selective androgen receptor modulators: the future of androgen therapy? Transl Androl Urol 2020; 9:S135&#x2013;S148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108998</ArticleId><ArticleId IdType="pubmed">32257854</ArticleId></ArticleIdList></Reference><Reference><Citation>Heje K, Andersen G, Buch A et al. High-intensity training in patients with spinal and bulbar muscular atrophy. J Neurol 2019; 266:1693&#x2013;1697.</Citation><ArticleIdList><ArticleId IdType="pubmed">31004213</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunseich C, Miller R, Swan T et al. Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomized, placebo-controlled trial. Lancet Neurol 2018; 17:1043&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6415539</ArticleId><ArticleId IdType="pubmed">30337273</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>